Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune-checkpoint inhibitor monoclonal antibody used for immunotherapy of lung cancer
Durvalumab (DUR) is a human monoclonal antibody used for the immunotherapy of lung cancer. It is a novel immune-checkpoint inhibitor, which blocks the programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) proteins and works to promote the normal immune responses that attack the tumour cell...
Main Authors: | Ibrahim A. Darwish, Nourah Z. Alzoman, Nehal N.Y. Khalil, Hany W. Darwish |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-06-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023029894 |
Similar Items
-
Novel highly sensitive chemiluminescence immunoassay for quantitation of durvalumab using a signal enhanced horseradish peroxidase-luminol-hydrogen peroxide reaction for detection system
by: Ibrahim A. Darwish, et al.
Published: (2023-08-01) -
A Novel Highly Sensitive Chemiluminescence Enzyme Immunoassay with Signal Enhancement Using Horseradish Peroxidase-Luminol-Hydrogen Peroxide Reaction for the Quantitation of Monoclonal Antibodies Used for Cancer Immunotherapy
by: Ibrahim A. Darwish, et al.
Published: (2023-04-01) -
Retraction notice to “Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune-checkpoint inhibitor monoclonal antibody used for immunotherapy of lung cancer” [Heliyon 9 (2023) e15782]
by: Ibrahim A. Darwish, et al.
Published: (2023-11-01) -
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
by: Fitzpatrick O, et al.
Published: (2021-11-01) -
Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10<sup>®</sup> to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies
by: Anne Emmanuelle Berger, et al.
Published: (2022-08-01)